Investors and analysts had eagerly awaited this data as a test of Novo’s case that it has a strong pipeline of drugs to ...

As of 11:05 a.m. ET, Novo Nordisk stock is down a disheartening 20.8%, while both Lilly and Viking stocks are up 4.4% apiece.

The treatment, called CagriSema, led patients to lose 20% of their weight at 68 weeks in a late-stage study when looking at ...

Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug ...

Novo Nordisk, Europe’s largest company by market value, faced a stock market bloodbath on Friday after disappointing results ...

New clinical trial data from Novo Nordisk raise questions for the broad landscape of obesity drug development and the way ...

Novo Nordisk shareholders were seeking on Friday to find out why such a high number of patients in the late-stage trial of ...

In a report released today, Michael Nedelcovych from TD Cowen maintained a Buy rating on Novo Nordisk (NVO – Research Report), with a price ...